Trending Topic

22 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained less certain. By synthesizing data from nine individual studies, this meta-analysis aimed to quantify the […]

Andrea R Genazzani, WCO IOF-ESCEO 2022: Hormone Replacement Therapy for Bone Loss Prevention Post Menopause (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 5th 2022

It was a pleasure to talk with Dr. Andrea R Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to find out when, in whom and for how long hormone replacement therapy should be administered for bone loss prevention post-menopause.

Hormone Replacement Therapy in post-menopause for bone loss prevention: when, how and for how long‘ was presented at WCO IOF-ESCEO 2022, 24-26 March, 2022

Questions

  1. When and in whom should HRT be considered for bone loss prevention? (1:16)
  2. How can HRT be administered? (3:45)
  3. For how long should HRT be administered? (5:59)

Disclosures: Andrea R Genazzani has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the WCO IOF-ESCEO annual meeting 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup